Cargando…
Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis
INTRODUCTION: After stage 3 CKD, the risk of adverse cardiovascular events increased significantly. Therefore, we performed a meta-analysis to investigate the cardiovascular protective effect of SGLT2 inhibitors in patients with stage 3/4 CKD with different baseline kidney function or underlying dis...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754287/ https://www.ncbi.nlm.nih.gov/pubmed/35020750 http://dx.doi.org/10.1371/journal.pone.0261986 |
_version_ | 1784632240124198912 |
---|---|
author | Li, Ning Zhou, Guowei Zheng, Yawei Lv, Dan Zhu, Xiangjun Wei, Ping Zheng, Min Liu, Shijia Zhou, Enchao Sun, Wei Zhang, Lu |
author_facet | Li, Ning Zhou, Guowei Zheng, Yawei Lv, Dan Zhu, Xiangjun Wei, Ping Zheng, Min Liu, Shijia Zhou, Enchao Sun, Wei Zhang, Lu |
author_sort | Li, Ning |
collection | PubMed |
description | INTRODUCTION: After stage 3 CKD, the risk of adverse cardiovascular events increased significantly. Therefore, we performed a meta-analysis to investigate the cardiovascular protective effect of SGLT2 inhibitors in patients with stage 3/4 CKD with different baseline kidney function or underlying diseases. METHOD: To identify eligible trials, we systematically searched the Embase, PubMed, Web of Science, and Cochrane library databases from inception to April 15, 2021. The primary cardiovascular outcome was defined as a combination of cardiovascular mortality and hospitalization due to heart failure. Baseline kidney functions (stage 3a CKD: eGFR45-59mL/min per 1.73m2, stage 3b CKD: eGFR30-44mL/min per 1.73m2, stage 4 CKD: eGFR<30mL/min per 1.73m2) and underlying diseases (Type 2 diabetes, heart failure (Preserved ejection fraction or reduced ejection fraction), atherosclerotic cardiovascular disease) were used to stratify efficacy and safety outcomes. The results were subjected to a sensitivity analysis to ensure that they were reliable. RESULTS: In the present study, a total of eleven trials were included that involved a total of 27,823 patients with stage 3/4 CKD. The treatment and control groups contained 14,451 and 13,372 patients, respectively. In individuals with stage 3/4 CKD, SGLT2 inhibitors reduced the risk of primary cardiovascular outcomes by 26% (HR 0.74, [95% CI 0.69–0.80], I(2) = 0.00%), by 30% in patients with stage 3a CKD (HR 0.70, [95% CI 0.59–0.84], I(2) = 18.70%), by 23% in patients with stage 3b CKD (HR 0.77, [95% CI 0.66–0.90], I(2) = 2.12%), and by 29% in patients with stage 4 CKD (HR 0.71, [95% CI 0.53–0.96], I(2) = 0.00%). The risk of primary outcomes was reduced by 29% (HR 0.71, [95% CI 0.63–0.80], I(2) = 0.00%) in patients with type 2 diabetes, by 28% (HR 0.72, [95% CI 0.56–0.93], I(2) = 37.23%) in patients with heart failure with preserved ejection fraction, by 21% (HR 0.79, [95% CI 0.70–0.89], I(2) = 0.00%) in patients with heart failure with reduced ejection fraction, and by 25% (HR 0.75, [95% CI 0.64–0.88], I(2) = 0.00%) in patients with atherosclerotic cardiovascular disease. CONCLUSIONS: For stage 3/4 CKD, SGLT2 inhibitors significantly decreased the risk of primary cardiovascular outcomes, and these benefits were consistent throughout the spectrum of different kidney functions, even in stage 4 CKD. There was no evidence of increased adverse outcomes across different baseline clinical complications, such as type 2 diabetes, heart failure, or atherosclerotic cardiovascular disease. |
format | Online Article Text |
id | pubmed-8754287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-87542872022-01-13 Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis Li, Ning Zhou, Guowei Zheng, Yawei Lv, Dan Zhu, Xiangjun Wei, Ping Zheng, Min Liu, Shijia Zhou, Enchao Sun, Wei Zhang, Lu PLoS One Research Article INTRODUCTION: After stage 3 CKD, the risk of adverse cardiovascular events increased significantly. Therefore, we performed a meta-analysis to investigate the cardiovascular protective effect of SGLT2 inhibitors in patients with stage 3/4 CKD with different baseline kidney function or underlying diseases. METHOD: To identify eligible trials, we systematically searched the Embase, PubMed, Web of Science, and Cochrane library databases from inception to April 15, 2021. The primary cardiovascular outcome was defined as a combination of cardiovascular mortality and hospitalization due to heart failure. Baseline kidney functions (stage 3a CKD: eGFR45-59mL/min per 1.73m2, stage 3b CKD: eGFR30-44mL/min per 1.73m2, stage 4 CKD: eGFR<30mL/min per 1.73m2) and underlying diseases (Type 2 diabetes, heart failure (Preserved ejection fraction or reduced ejection fraction), atherosclerotic cardiovascular disease) were used to stratify efficacy and safety outcomes. The results were subjected to a sensitivity analysis to ensure that they were reliable. RESULTS: In the present study, a total of eleven trials were included that involved a total of 27,823 patients with stage 3/4 CKD. The treatment and control groups contained 14,451 and 13,372 patients, respectively. In individuals with stage 3/4 CKD, SGLT2 inhibitors reduced the risk of primary cardiovascular outcomes by 26% (HR 0.74, [95% CI 0.69–0.80], I(2) = 0.00%), by 30% in patients with stage 3a CKD (HR 0.70, [95% CI 0.59–0.84], I(2) = 18.70%), by 23% in patients with stage 3b CKD (HR 0.77, [95% CI 0.66–0.90], I(2) = 2.12%), and by 29% in patients with stage 4 CKD (HR 0.71, [95% CI 0.53–0.96], I(2) = 0.00%). The risk of primary outcomes was reduced by 29% (HR 0.71, [95% CI 0.63–0.80], I(2) = 0.00%) in patients with type 2 diabetes, by 28% (HR 0.72, [95% CI 0.56–0.93], I(2) = 37.23%) in patients with heart failure with preserved ejection fraction, by 21% (HR 0.79, [95% CI 0.70–0.89], I(2) = 0.00%) in patients with heart failure with reduced ejection fraction, and by 25% (HR 0.75, [95% CI 0.64–0.88], I(2) = 0.00%) in patients with atherosclerotic cardiovascular disease. CONCLUSIONS: For stage 3/4 CKD, SGLT2 inhibitors significantly decreased the risk of primary cardiovascular outcomes, and these benefits were consistent throughout the spectrum of different kidney functions, even in stage 4 CKD. There was no evidence of increased adverse outcomes across different baseline clinical complications, such as type 2 diabetes, heart failure, or atherosclerotic cardiovascular disease. Public Library of Science 2022-01-12 /pmc/articles/PMC8754287/ /pubmed/35020750 http://dx.doi.org/10.1371/journal.pone.0261986 Text en © 2022 Li et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Li, Ning Zhou, Guowei Zheng, Yawei Lv, Dan Zhu, Xiangjun Wei, Ping Zheng, Min Liu, Shijia Zhou, Enchao Sun, Wei Zhang, Lu Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis |
title | Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis |
title_full | Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis |
title_fullStr | Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis |
title_full_unstemmed | Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis |
title_short | Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis |
title_sort | effects of sglt2 inhibitors on cardiovascular outcomes in patients with stage 3/4 ckd: a meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754287/ https://www.ncbi.nlm.nih.gov/pubmed/35020750 http://dx.doi.org/10.1371/journal.pone.0261986 |
work_keys_str_mv | AT lining effectsofsglt2inhibitorsoncardiovascularoutcomesinpatientswithstage34ckdametaanalysis AT zhouguowei effectsofsglt2inhibitorsoncardiovascularoutcomesinpatientswithstage34ckdametaanalysis AT zhengyawei effectsofsglt2inhibitorsoncardiovascularoutcomesinpatientswithstage34ckdametaanalysis AT lvdan effectsofsglt2inhibitorsoncardiovascularoutcomesinpatientswithstage34ckdametaanalysis AT zhuxiangjun effectsofsglt2inhibitorsoncardiovascularoutcomesinpatientswithstage34ckdametaanalysis AT weiping effectsofsglt2inhibitorsoncardiovascularoutcomesinpatientswithstage34ckdametaanalysis AT zhengmin effectsofsglt2inhibitorsoncardiovascularoutcomesinpatientswithstage34ckdametaanalysis AT liushijia effectsofsglt2inhibitorsoncardiovascularoutcomesinpatientswithstage34ckdametaanalysis AT zhouenchao effectsofsglt2inhibitorsoncardiovascularoutcomesinpatientswithstage34ckdametaanalysis AT sunwei effectsofsglt2inhibitorsoncardiovascularoutcomesinpatientswithstage34ckdametaanalysis AT zhanglu effectsofsglt2inhibitorsoncardiovascularoutcomesinpatientswithstage34ckdametaanalysis |